Comparison between fractional CO2 laser-triamcinolone injection combination therapy and triamcinolone injection monotherapy for keloid

M. Yulianto Listiawan,1 Dwi Murtiastuti,1 Willy Sandhika,2 Bram Rachmantyo,1 Putri Hendria Wardhani1

1Department of Dermatology and Venereology; 2Department of Anatomic Pathology, Faculty of Medicine, Airlangga University, Dr. Soetomo General Hospital, Surabaya, Indonesia

Abstract

The histopathologic view of keloid shows dense fibroblasts and bundles of collagen throughout dermis. Treatment that completely cure keloid still not exist, although there are many treatment options. The monotherapy fractional CO2 laser shows good results, but is still as an adjuvant therapy. Fractional CO2 laser affects fibroblast and its functions in producing collagen. The combination therapy will combine the selective photothermolysis effect of CO2 lasers with antimitotic and antiinflammatory effects of corticosteroids. This study was an open trial with parallel design that compared fractional CO2 laser-intralesional triamcinolone acetonide combination therapy (treatment group) and intralesional triamcinolone acetonide (control group) in keloid patients with collagen density as evaluation parameter. The dose of triamcinolone was 10 mg/ml of 0.05-0.1 ml/cm² of keloid. Fractional CO2 laser energy setting was 10-20 ml. The decrease of collagen density in control and treatment group was significant (p=0.008 and p=0.001), although the decrease difference between control and treatment group was not significant (p=0.328). The collagen density that decrease in a shorter time shows that fractional CO2 laser could be a good combination therapy.

Introduction

Keloid is benign hyperplasia of the fibrous tissue of the skin. Keloid is scar tissue that grows beyond the border of the initial injury. Symptoms that can occur are pain and itching. The histopathologic view shows dense fibroblasts and bundles of collagen appearing throughout the thickness of the dermis. Fibroblast apoptotic rate in the keloid is lower than in the normal skin.1,2 The excessive collagen is due to an imbalance between the formation and degradation of extracellular matrix.3,5 Keloidmore affects African, Asian and Latin American ethnicities. Vulnerability genetically increases the risk of keloid 15% greater than in the population.4 Prevalence of keloid patients treated in Dermatovenerology Department Dr. Soetomo Hospital Surabaya is 1.4% (83 patients) by 2013, 1.6% (80 patients) by 2014, and 1.5% (74 patients) by 2015. The number of patients is a combination of the number of new and old patients. Keloid can result in a physical and psychological problem. Physical problems may be itchy, rigid skin, scar contractures, and pain symptoms. Psychological problems include confidence disorders, impaired daily activities, anxiety, and depression.3,6 There is no single treatment modality that is considered superior for the treatment of keloids. Treatment that cure the keloid completely still do not exist, although there are many treatment options available.4,6

First-line keloid therapy is intraleral corticosteroid injection, but give more results in small and early-stage keloid.7 Second-line therapy, surgical excision, needs to be considered if the keloid does not improve after first-line therapy for 12 months. Surgical therapy is not recommended as a single therapy because the high rate of keloid recurrence (50-100%), can even form a larger keloid of early keloids. Second-line therapy that can be used in addition to surgical excision is laser.1,3

Intralesional triamcinolone acetonide injection therapy showed 50% -100% efficacy. The recurrence rate of this therapy reaches 33% in 1 year and 50% in 5 years.6 The Carbon dioxide (CO2) laser is an ablative laser, a continuous ablation effectively treating the keloid, but a long wound healing time of 4-8 weeks. The recurrence rate reached 92.3%. Continuous CO2 laser followed by intralesional triamcinolone acetonide injection has better effectiveness than CO2 laser therapy or triamcinolone acetonide monotherapy. The rate of keloid recurrence that received combination therapy is reduced to 15.4%.7 Fractional CO2 lasers begin to be used for keloid because it has a shorter healing period. The monotherapy fractional CO2 laser shows good results, without recurrence after one year. The study was a case series with 8 patients with hypertrophic scars and keloids. Fractional CO2 lasers are still an adjuvant therapy because no studies have demonstrated the superiority of CO2 lasers over intralesional triamcinolone acetonide injection.8

The combination therapy of fractional CO2 laser with intralesional triamcinolone acetonide injection for the treatment of keloid has never been studied in Dr. Soetomo Hospital Surabaya. Fractional CO2 laser is an ablative laser emitted in the form of laser light columns forming a microscopic treatment zone (MTZ). The MTZ is partially ablated area and the other part is still intact, allowing for a faster healing time compared to continuous CO2 lasers.7,9 Fractional CO2 laser affects fibroblast and its functions in producing collagen.9 The combination therapy will combine the selective photothermolysis effect of CO2 lasers with the antimitotic and antiinflammatory effects of corticosteroids. Keloid to be studied excluding keloid in the face area. This research is expected to know the effectiveness of combination therapy of CO2 fractional and injection of triamcinolone acetonide to keloid patient with collagen density parameter.

Materials and Methods

This study was an open trial with parallel design methods that compared combination therapy fractional CO2 laser with intralesional triamcinolone acetonide (treatment group) and monotherapyintralesional triamcinolone acetonide (control group) in patients with keloids. The sample of the
The study was conducted at the Skin Surgery Division Dermatoveneurology Clinic of Dr. Soetomo Hospital Surabaya. The number of samples in the treatment group was 13 patients and in the control group was 13 patients. Data collection performed by filling the data collection sheet. Data were analyzed by using MANOVA (Multivariate Analysis of Variance) test.

The inclusion criteria are keloid patients, including new and old keloid, age 15-64 years. Patients have not been treated with triamcinolone acetonide injections, if they have undergone such therapy it should be longer than 4 weeks after the last therapy. Patients with keloids who relapse after previous keloid therapy. The general condition of the patient is good. Willing to follow the research and sign the informed consent.

The exclusion criteria are patients with keloids on the face. Keloid size is more than 1% of skin surface area. Patients with systemic disease requiring immunosuppression therapy, (e.g. systemic lupus erythematosus and pemphigus). Patients with skin infections, diabetes mellitus, pregnancy, and breastfeeding. Patients who had been on CO2 laser therapy for keloid in the last 6 months.

Biopsy was taken from the lesion area by using punch biopsy - 4 mm, before the biopsy was performed local anesthesia first, then the punch instrument was rotated while pressed to a sufficient depth. The tissue is lifted and released from the underlying skin tissue. Bleeding on the open wound was stopped. Biopsy performed 2 times, before and after therapy. The location of the initial biopsy in the middle of a keloid lesion. Final biopsy is taken in the same lesion, but in different locations. Collagen density is a proportion of collagen fiber in a one visual field of Masson’s trichromestaining keloid slide with 400 times magnification.

Intralesional triamcinolone acetonide are performed according to the standard, using a 1 cc syringe and 25-gauge needle. The dose used is 10 mg/ml of 0.05-0.1 ml/cm² of keloid. Direct injection is done to the keloid mass with the needle pointing downward. Pressure to injection sites after injection is necessary to prevent drug fluids escaping from the lesions. Administration in 1 therapy did not exceed 30 mg. Therapy was done 2 times with a 3-week break.

Fractional CO2 laser therapy is a CO2 ablation laser therapy in fractional mode with 10-20 mJ energy. Less energy for older and soft lesions, larger for new and hard lesions. 2.5% lidocaine anesthetic cream and 2.5% prilocaine were applied and 1 hour occlusive before laser therapy, then removed shortly before laser was done. The patient’s eyes are covered with eye protector, doctors wear gloves and masks, and protective goggles. Keloid is disinfect with 70% alcohol. The hand piece is directed perpendicular to the lesion, then the foot pedal is stepped on to fire the laser. The lesions were cooled with a cool, sterile 0.9% NaCl gauze. Treatment was performed in the treatment group 1 times before intralesional triamcinolone injection.

**Results**

This study involved more female patients than male patients, but the sex of the patients between the control group and the treatment was homogeneous (p=0.694). The largest number of patients by age is in the 15-24 age group. Results of age data processing of keloids obtained the youngest age is 18 years old and the oldest is 58 years. The age group of patients between the controls did not differ from treatment group with p = 0.537.

The shortest length of illness keloid in the study subjects was for 6 months and included in the group of 0.5-1 years of illness. Most research subjects suffer from keloid more than 4 years. The longest illness is 15 years. The homogeneity test showed that the length of keloid pain between the control group and the treatment group was not homogeneous. A total of 17 patients (65.4%) had already been on treatment for keloids, but only 9 of 26 patients (34.6%) were on standard treatment of triamcinolone acetonide injections.

The collagen density in the control and treatment group decreased significantly (p=0.008 & p=0.001, respectively). The average collagen density in the control group decreased from 87.69±7.00%/visual field to 79.46±7.98% at 3 weeks after the last treatment, while the mean collagen density in the treatment group decreased from 87.46±7.98% to 79.31±7.58% at 3 weeks after the last treatment.

The decrease difference of collagen density between the control group and the treatment group was not significant (Table 1). The mean degradation of collagen density from pretreatment to post-treatment in the control group was -5.69±6.41%/visual field, whereas the mean decrease of collagen density from pretreatment to post-treatment in the treatment group was -8.38±7.31%/visual field. The mean difference of collagen density degradation between the two groups was -2.69 with p=0.328.

**Discussion**

This study is an open controlled clinical trial that aimed to compare the effectivity of CO2 fractional laser and triamcinolone acetonide injections combination therapy with standard therapy of triamcinolone acetonide monotherapy. After 6 months sampling, 26 study participants fulfilled the inclusion criteria. Study participants who have been injected with triamcinolone acetonide should be longer than 4 weeks before the study begins. All of the enrolled study participants have not received a fractional CO2 laser therapy. The studied keloid does not include the face, ears, and neck area. All study participants had good general conditions and did not have systemic disease.

The age of study participants was determined in the range of 15-64 years. No younger than 15 years old because of concern the patient can not cooperate during the research procedure. The age of 15 and above is also selected according to the WHO adult criteria. Not older than 64

<table>
<thead>
<tr>
<th>Week 0</th>
<th>Week 3</th>
<th>Week 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin biopsy and lesion measurement</td>
<td>2nd triamcinolone injection</td>
<td>Skin biopsy and post-treatment measurement of the lesion</td>
</tr>
</tbody>
</table>

Table 2. Result of analysis of difference of degradation of collagen density between control and treatment group using T-Test.

<table>
<thead>
<tr>
<th>Decrease density of collagen</th>
<th>Mean (SD)</th>
<th>Difference</th>
<th>CI 95%</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control group</td>
<td>-5.69(6.41)</td>
<td>-2.69</td>
<td>(-2.87)-(8.26)</td>
<td>0.328</td>
</tr>
</tbody>
</table>

[Dermatology Reports 2019; 11(s1):8032] [page 39]
years-old because the invasive procedure of this study is feared to affect the general condition of the patient. The mean age of the subjects in this study was 29.4 years-old. Most participants were in the 15-24 year age group (53.8%), followed by the 25-34 year age group. Participants of female sex (57.7%) slightly more than men.

According to Chike-Obi et al. keloid can occur at all ages, the incidence is highest at the age of 11-30 years, and slightly more in women. Age between the treatment group and the control group in this study did not differ significantly (p=0.537), and also the sex of the study subjects between the two study groups (p=0.694).

The duration of illness was not homogeneous between the control group and the treatment group, as there were patient who suffer keloid for 15 years in the treatment group. The patient was not excluded from the study because it met the inclusion criteria. The length of illness in study subjects varied from 6 months to 15 years. A total of 9 patients (34%) had ever undergone standard treatment, intralesional triamcinolone acetonide injections. A total of 4 patients are still undergoing several injection sessions, so there is no change from the initial condition. These patients complain of pain during the injection so they underwent the treatment regularly. Patients who did not undergo standard treatment will not get the maximum treatment result. There were 3 patients who had undergone surgical removal of keloid, then the three patients had keloid relapse. This is in accordance with the literature which states that keloid recurrence after excision is 45-100% if not accompanied by adjunct therapy.

Histopathological parameters were rare in the study of keloids, most of which were parameters of scar assessment scores. This study attempts to prove that triamcinolone acetonide and combination therapy can decrease the collagen density. Triamcinolone significantly decreased the collagen density in the control and combination therapy group, but the difference of degradation was insignificant (Table 1). It could be caused by the laser therapy in the combination therapy was performed only once and the evaluation time was only 6 weeks after treatment.

Triamcinolone acetonide in the both group suppresses fibroblast proliferation and enhance fibroblast degeneration, thus decrease collagen production. Triamcinolone acetonide also has vasoconstriction effect that diminish vascularization to keloid. The fractional CO₂ lasers decrease the collagen density in a some ways. It enhance fibroblast proliferation, but diminish TGF-β that has pivotal role in collagen synthesis. It also shorten collagen fiber to one-third of initial length. The MTZ depth that formed by fractional CO₂ laser is about 400μm. The depth has reached the depth of papillary dermis, so that MTZ can be a depot and assist in the distribution of injected triamcinolone acetonide. The collagen density decreased more significantly after fractional CO₂ laser-triamcinolone injection combination therapy in only 6 weeks follow up (1 laser and 2 times triamcinolone acetonide injection) than after triamcinolone injection alone. It suggest that the combination therapy gives a synergistic effect.

Conclusions
The collagen density that decrease significantly in a shorter time shows that fractional CO₂ laser-triamcinolone acetonide injection could be a good combination therapy. Fractional CO₂ laser gives a synergistic effect to intralesional triamcinolone acetonide injection. The combination therapy is an effective keloid therapy and may become the alternative for intralesional triamcinolone acetonide monotherapy. Intralesional triamcinolone acetonide monotherapy remains the mainstay for keloid therapy, because the combination therapy still not showed a significant deference to triamcinolone acetonide injection monotherapy.

References